ALG-097558, Publications

Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment

Pevifoscorvir-sodium, Publications

High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy

ALG-097558, Publications

Structural basis for pan-coronavirus inhibition of 3CL protease

Pevifoscorvir-sodium, Publications

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial

ALG-055009, Publications

Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists

Pevifoscorvir-sodium, Publications

Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks

ALG-055009, Publications

Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists

Preclinical, Publications

Explorations Towards the Selection of a Potential Best-in-Class HBV ASO

Preclinical, Publications

An antisense oligonucleotide strategy targeting the Hepatitis Delta Virus

Pevifoscorvir-sodium, Publications

A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants